High Falls Advisors Inc Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

High Falls Advisors Inc increased its holdings in Johnson & Johnson (NYSE:JNJ) by 15.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,186 shares of the company’s stock after acquiring an additional 296 shares during the quarter. High Falls Advisors Inc’s holdings in Johnson & Johnson were worth $354,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Innealta Capital LLC bought a new position in Johnson & Johnson in the second quarter worth about $27,000. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $31,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $40,000. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target for the company. Wells Fargo & Company boosted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Guggenheim raised their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Royal Bank of Canada raised their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.67.

Johnson & Johnson Stock Up 0.2 %

Shares of Johnson & Johnson stock opened at $149.61 on Tuesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company’s 50 day moving average is $157.84 and its 200 day moving average is $156.40. The company has a market cap of $360.20 billion, a price-to-earnings ratio of 21.65, a price-to-earnings-growth ratio of 2.65 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period last year, the business posted $2.66 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.